Fed Regist. 2004 Jun 8;69(110):32010-1.
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "Q1E Evaluation of Stability Data." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). This guidance is a supplement to an ICH guidance entitled "Q1A(R2) Stability Testing of New Drug Substances and Products," which was revised from Q1A(R) and published in the Federal Register of November 21, 2003 (68 FR 65717). It is intended to provide guidance on how to use stability data, generated in accordance with the principles outlined in Q1A(R2), to propose a retest period for the drug substance and a shelf life for the drug product.
美国食品药品监督管理局(FDA)宣布发布一份题为《Q1E稳定性数据评估》的指南。该指南是在人用药品注册技术要求国际协调会议(ICH)的主持下制定的。本指南是对ICH指南《Q1A(R2)新药原料和产品的稳定性测试》的补充,该指南由Q1A(R)修订而来,并于2003年11月21日发布在《联邦公报》上(68 FR 65717)。其目的是就如何使用根据Q1A(R2)中概述的原则生成的稳定性数据,来提出原料药的复验期和药品的有效期提供指导。